Market Research Reports Global Non-Alcoholic Fatty Liver Disease (NAFLD) M | Page 2

Alcoholic Fatty Liver Disease (NAFLD). The common symptoms include fatigue, weakness, weight loss
and others. The Non-Alcoholic Fatty Liver Disease (NAFLD) diagnosis requires the combination of
different tests such as blood test, ultrasound, CT scan, MRI scan, and liver biopsy. The two types of
Non-Alcoholic Fatty Liver Disease (NAFLD) include simple fatty liver and Nonalcoholic Steatohepatitis
(NASH).
The Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market is segmented on the basis of Type,
Distribution Channels and Region. On the basis of Type, the market is sub-segmented into
Antioxidants, Thiazolidinedione, Biguanides, Lipid lowering Agents, FXR Receptor Agonist and others.
On the basis of Distribution Channels, the market is divided into Hospital Pharmacy, Retail Pharmacy,
Drug Stores, Online Pharmacy and others.
In terms of the regional analysis, North America is estimated to lead the Global Non-Alcoholic Fatty
Liver Disease (NAFLD) Market due to increase in prevalence of diabetes and cardiovascular diseases
in US. Large number of manufacturers exists in the market, with large number of customer base.
APAC market is also projected to experience high growth in the near future owing to factors such as,
increase in healthcare expenditure, rising standard of living, lifestyle changes- attributed to better
healthcare and awareness of the cost-effective treatment process with government grants and
funding for acceleration in research and development activities.
Industry News:
Daewoong Pharmaceutical (March 14, 2019) – Daewoong Pharmaceutical leads innovation of local
business by focusing on technology transfer with Trapaco, the largest pharmaceuticals company in
Vietnam – Daewoong Pharmaceutical (CEO Sengho Jeon) announced on the 14th that they started
the kick-off meeting for technology transfer and local production with Trapaco, one of ‘Big 2’
pharmaceutical companies in Vietnam whose shares were acquired in 2017. With this technology
transfer and production, Trapaco will be able to improve their technology in the ethical drugs (ETC)
and Daewoong Pharmaceutical will be able to join the local bidding group in Vietnam.
Daewoong Pharmaceutical has selected eight products to be produced and supplied at Trapaco’s
new factory, including Urusa, with plans to transfer the production technology for ingredient
sourcing, equipment purchasing, analyzing, and test production during 2019 and start selling the
products in 2021. Trapaco will create the sales and marketing organizations for Daewoong
Pharmaceutical’s products to take charge of production, sale, and distribution in Vietnam.
Top Leading Key Manufacturers are: Conatus Pharmaceuticals, Daewoong Pharmaceutical, Galmed
International, Kyorin Pharmaceutical, Metabolic Solutions Development, Novartis AG, Phenex
Pharmaceuticals, Raptor Pharmaceuticals, TCM Biotech International, Tobira Therapeutics, Verva
Pharmaceuticals, Zafgen and others. New product launches and continuous technological
innovations are the key strategies adopted by the major players.
Purchase this report online with 125 Pages, List of Tables & Figures and in-depth Table of Contents
on “Global Non-Alcoholic Fatty Liver Disease (NAFLD) Market Report 2019” @
https://www.businessindustryreports.com/buy-now/115942/single .
Region segment: This report is segmented into several key regions, with sales, revenue, market
share (%) and growth Rate (%) of Non-Alcoholic Fatty Liver Disease (NAFLD) in these regions, from